Investigation of complement activity between generic drug and barand-name drug for the use of anticoagulant during blood apheresis therapy

Investigation of complement activity between generic drug and barand-name drug for the use of anticoagulant during blood apheresis therapy - The effect of anticoagulant for complement activity during hemodiafiltration therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029038

Enrollment

Registered

2017-09-07

Start date

2017-09-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Generic drug will use for the anticoagulant for the patients with receiving continuous hemodiafiltration therapy. Brand name drug will use for the anticoagulant for the patients with receiving contin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients receiving blood purification thrapy

Exclusion criteria

Exclusion criteria: age under 20 y.o.

Design outcomes

Primary

Measure	Time frame
The difference of the complement activity with the use of brand name drug or generic drug	—

Secondary

Measure	Time frame
The difference of the coagulation activity or cytokine concentration with the use of brand name drug or generic drug	—

Countries

Japan

Contacts

Public ContactKazunori Fujino

Shiga University of Medical Science Critical and Intensive care medicine

kfujino@belle.shiga-med.ac.jp077-548-2929

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026